Literature DB >> 2924610

Homogeneity of bronchopulmonary distribution of 99mTc aerosol in normal subjects and in cystic fibrosis patients.

B L Laube1, J M Links, N D LaFrance, H N Wagner, B J Rosenstein.   

Abstract

We characterized the bronchopulmonary distribution of a 0.9 percent saline aerosol (1.12 microM) labelled with 99mTc sulfur colloid in nine normal subjects and five patients with CF. Homogeneity of distribution was quantified using indices derived from computerized analysis of Anger camera pulmonary images including skew (a measure of distribution asymmetry) and kurtosis (a measure of distribution range). Aerosol clearance in 97 minutes (a measure of large, central airway deposition) was also assessed. Values of skew and kurtosis were reproducible for the patients with CF and were significantly elevated compared to the normal subjects. Reproducibility of skew and kurtosis were not studied in the normal subjects. Clearance was not significantly different in the two groups. We conclude that the bronchopulmonary distribution of this radioaerosol is nonuniform in patients with CF, compared to normal subjects, and clearance may be impaired in patients with CF who are severely ill.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2924610     DOI: 10.1378/chest.95.4.822

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

Review 1.  Structure and function of the mucus clearance system of the lung.

Authors:  Brenda M Button; Brian Button
Journal:  Cold Spring Harb Perspect Med       Date:  2013-08-01       Impact factor: 6.915

2.  Heterogeneity of Particle Deposition by Pixel Analysis of 2D Gamma Scintigraphy Images.

Authors:  William D Bennett; Miao Xie; Kirby Zeman; Harry Hurd; Scott Donaldson
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-11-13       Impact factor: 2.849

3.  Exogenous pulmonary surfactant as a drug delivering agent: influence of antibiotics on surfactant activity.

Authors:  A van 't Veen; D Gommers; J W Mouton; J A Kluytmans; E J Krijt; B Lachmann
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

4.  Improvement of nebulised antibiotic delivery in cystic fibrosis.

Authors:  D Wilson; M Burniston; E Moya; A Parkin; S Smye; P Robinson; J Littlewood
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

Review 5.  Clinical applications of pulmonary delivery of antibiotics.

Authors:  Patrick A Flume; Donald R VanDevanter
Journal:  Adv Drug Deliv Rev       Date:  2014-10-22       Impact factor: 15.470

6.  Assessment of ejection fraction with Tl-201 gated SPECT in myocardial infarction: Precision in a rest-redistribution study and accuracy versus planar angiography.

Authors:  E Itti; J Rosso; P Damien; M Auffret; J P Thirion; M Meignan
Journal:  J Nucl Cardiol       Date:  2001 Jan-Feb       Impact factor: 5.952

7.  Transduction of Surface and Basal Cells in Rhesus Macaque Lung Following Repeat Dosing with AAV1CFTR.

Authors:  William B Guggino; Murali K Yanda; Cristina V Cebotaru; Liudmila Cebotaru
Journal:  Hum Gene Ther       Date:  2020-09       Impact factor: 5.695

8.  Influence of pulmonary surfactant on in vitro bactericidal activities of amoxicillin, ceftazidime, and tobramycin.

Authors:  A van 't Veen; J W Mouton; D Gommers; J A Kluytmans; P Dekkers; B Lachmann
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

Review 9.  Nebulized antibiotics in cystic fibrosis.

Authors:  Isabelle Sermet-Gaudelus; Yann Le Cocguic; Agnés Ferroni; Marlène Clairicia; Joel Barthe; Jan-Pierre Delaunay; Valentine Brousse; Gérard Lenoir
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

10.  The use of an alternate side lying positioning strategy during inhalation therapy does not prolong nebulisation time in adults with Cystic Fibrosis: a randomised crossover trial.

Authors:  Ruth L Dentice; Mark R Elkins; Genevieve M Dwyer; Peter T P Bye
Journal:  BMC Pulm Med       Date:  2018-01-08       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.